Weight Management Clinical Trial
— NATICOLOfficial title:
Effect of a Fish Collagen Peptide Food Supplement on the Weight and Body Composition of Healthy Volunteers in Overweight
Verified date | December 2022 |
Source | Institut Pasteur de Lille |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Fish collagen hydrolysates or peptides orally administered have been investigated in recent clinical trials in human health. These peptides have been evaluated in various biological and medical fields including skin aging, osteoarticular apparatus, muscle and more recently in energy metabolism in both animals and humans. However, very few studies investigated the effect of fish collagen peptides on weight, body composition or glycemic response. Recently, it has been shown that the consumption of fish collagen peptides (Naticol®) limits weight gain and increase in fat mass in a mouse model made obese by a hyperlipidic diet. Since these results have never been observed in humans, this pilot study proposes to answer this question.
Status | Completed |
Enrollment | 40 |
Est. completion date | July 30, 2019 |
Est. primary completion date | June 30, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Men in overweight (BMI between 25kg/m² and 30kg/m²) - Aged from 18 and 60 years - Having signed the informed consent form; - Susceptible to follow the constraints generated by the study; Exclusion Criteria: - Subject treated for type 1 or 2 diabetes, or for any other metabolic disorder (severe dyslipidemia: TG> 3 g / L and total cholesterol> 2.5 g / L); - Subject with untreated and uncorrected high blood pressure; - Subject with untreated or uncorrected dysthyroidism by drug therapy; - Subject with a serious general illness that may prevent his or her ability to complete the trial or that could bias the results of the study; - Subject consuming antibiotic treatment in the month prior to inclusion; - Subject treated with steroidal anti-inflammatory drugs, anabolic steroids, anticoagulants or corticosteroids; - Subject knowing allergy to fish or fish collagen; - Subject taking any dietary supplement or drug that may interact with the results of the study or that could alter the bioavailability of the product under study; - Subject following or having followed a low-calorie diet (energy intake <1500 kcal / day) in the 3 months preceding inclusion and / or likely to undertake this diet during the test; - Subject having lost more than 5% of his initial weight during the last 3 months; - Subject following a special diet: eg. vegetarian, macrobiotic diet, high protein diet; - Subject with diagnosed eating disorders (anorexia, bulimia); - Subject with gastrointestinal malabsorption such as celiac disease, Crohn's disease or lactose intolerance; - Subject having undergone bariatric surgery; - Subject with excessive alcohol consumption at more than 3 drinks a day ; - Subject planning to modify his tobacco consumption (eg weaning) or his level of physical activity (significant increase) before the end of the intervention period; - Subject having an aversion to the grapefruit aroma; - Subject unable to understand or adhere to the protocol; - Subject participating in another clinical study or exclusion period from another study; |
Country | Name | City | State |
---|---|---|---|
France | NutrInvest - Institut Pasteur de Lille | Lille | Nord |
Lead Sponsor | Collaborator |
---|---|
Institut Pasteur de Lille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Weight of participants | Weight is expressed in kilograms | 0 and 3 months | |
Secondary | Body composition par DXA analysis | Fat mass is expressed in kg and percent, muscle mass in kg and percent. | 0 and 3 months | |
Secondary | Waist circumference | Data are expressed in centimeters | 0 and 3 months | |
Secondary | Lipid profile in plasma | Total cholesterol, HDL cholesterol, LDL cholesterol, and Triglycerides. Data are expressed in g/L and in mmol/L | 0 and 3 months | |
Secondary | Glycemia level in plasma | Data are expressed in g/L and mmo/L | 0 and 3 months | |
Secondary | Insulin level in plasma | Data are expressed in µU/ml | 0 and 3 months | |
Secondary | HOMA index | This index indicates the insulin resistance and was calculated as follow : HOMA [(glycémie mmol/l X insulinémie µU/ml) à jeun / 22,5] | 0 and 3 months | |
Secondary | Physical activity intensity | Score obtained via Ricci and Gagnon questionnaire. The questionnaire contains 9 questions ; score could be between 9 and 45 points.
under 18 points : inactive behavior between 19 and 35 points : active behavior over 35 points : very active behavior |
0 and 3 months | |
Secondary | Pro-inflammatory cytokines concentration | Assay for TNFalpha, IL-1beta and IL-6 in plasma | 0 and 3 months | |
Secondary | Microbiota analysis | Rate comparison of different bacteria families | 0 and 3 months | |
Secondary | Height | centimeters | 0 | |
Secondary | Body mass index | kg/m² | 0 and 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03360058 -
Obesity and Type 2 Diabetes - Raising the Issue of Weight Management in Primary Care
|
N/A | |
Active, not recruiting |
NCT05400187 -
Body Composition Assessment and Smart-phone Based Counselling on Healthy Eating and Weight Management
|
N/A | |
Completed |
NCT01731197 -
Satiating Effects of Isolated Soy Proteins
|
N/A | |
Recruiting |
NCT06147752 -
Mobile Internet Healthcare and Three Disciplines Co-management Intervention for Overweight/Obese Prediabetic Patients
|
N/A | |
Not yet recruiting |
NCT06428695 -
Education Session to Improve Program Adherence
|
N/A | |
Completed |
NCT06312917 -
Effect of Physical Activity Intervention on Overweight and Obese Patients With Endometrial Cancer
|
N/A | |
Completed |
NCT01575886 -
Enhancing Teachable Moment Communication for Smoking Cessation and Weight Management
|
N/A | |
Completed |
NCT01030354 -
Effects of Protein-Enriched Meal on Liver, Kidney or Bone: a Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Completed |
NCT04260997 -
Effect of a Probiotic, Lactobacillus Gasseri BNR17, on Body Composition and Weight Management in Overweight Adults
|
N/A | |
Enrolling by invitation |
NCT01511393 -
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
|
||
Recruiting |
NCT05257239 -
Acceptability and User Perceptions of Artificial Intelligence-based Mobile Applications Adoption for Weight Management: A Sequential Explanatory Study
|
||
Completed |
NCT00542009 -
A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight
|
Phase 2 | |
Recruiting |
NCT05869604 -
Healthy Lifestyles After Cancer for Adolescents and Young Adults: A Program to Reduce Cardiovascular Risk Factors
|
N/A | |
Unknown status |
NCT00866151 -
A to Z Study Follow-up: Collection of DNA Data From Buccal Swabs
|
N/A | |
Active, not recruiting |
NCT05813795 -
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
|
Phase 3 | |
Recruiting |
NCT05534386 -
A Self-management Based Survivorship Intervention for Chinese Cancer Survivors
|
N/A |